Advanced search
Publication Cover
Current Medical Research and Opinion Volume 24, 2008 - Issue 3
Submit an article Journal homepage
253
Views
14
CrossRef citations to date
0
Altmetric
Original Article

Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands

Jeroen P. Jansen Mapi Values, Houten, The NetherlandsCorrespondence[email protected]
,
Sabine Gaugris Outcome Research, Merck & Co., Inc., Whitehouse Station, New Jersey, USA
,
Gert Bergman Mapi Values, Houten, The Netherlands
&
Shuvayu S. Sen Outcome Research, Merck & Co., Inc., Whitehouse Station, New Jersey, USA
Pages 671-684 | Accepted 28 Nov 2007, Published online: 24 Jan 2008

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Bruce Y Lee & Mirat Shah. (2012) Prevention of influenza in healthy children. Expert Review of Anti-infective Therapy 10:10, pages 1139-1152.
Read now
Steven Boonen. (2009) Impact of treatment efficacy and dosing frequency on cost-effectiveness of bisphosphonate treatment for osteoporosis: a perspective. Current Medical Research and Opinion 25:10, pages 2335-2341.
Read now
Andrea J. Singer & Steven Boonen. (2008) Osteoporosis management: translating research into optimal fracture protection II. Current Medical Research and Opinion 24:6, pages 1789-1796.
Read now

Articles from other publishers (11)

Jieyi Li, Marco Viceconti, Xinshan Li, Pinaki Bhattacharya, David M. J. Naimark & Anwar Osseyran. (2023) Cost-Effectiveness Analysis of CT-Based Finite Element Modeling for Osteoporosis Screening in Secondary Fracture Prevention: An Early Health Technology Assessment in the Netherlands. MDM Policy & Practice 8:2.
Crossref
Marcel H. Schöttler, Friso B. Coerts, Maarten J. Postma, Cornelis Boersma & Mark H. Rozenbaum. (2023) The Effect of the Drug Life Cycle Price on Cost-Effectiveness: Case Studies Using Real-World Pricing Data. Value in Health 26:1, pages 91-98.
Crossref
Md Azharuddin, Mohammad Adil, Rashid Ali Khan, Pinaki Ghosh, Prem Kapur & Manju Sharma. (2020) Systematic evidence of health economic evaluation of drugs for postmenopausal osteoporosis: A quality appraisal. Osteoporosis and Sarcopenia 6:2, pages 39-52.
Crossref
Pilar Sáez-López, Iñigo Etxebarria-Foronda, Maria Pilar Mesa Lampre, Noelia Alonso García & Natalia Sánchez Hernández. (2019) Efficacy, cost, and aspects to take into account in the treatment of osteoporosis in the elderly. Revista Española de Geriatría y Gerontología 54:3, pages 156-167.
Crossref
Mickaël Hiligsmann, Silvia M. Evers, Wafa Ben Sedrine, John A. Kanis, Bram Ramaekers, Jean-Yves Reginster, Stuart Silverman, Caroline E. Wyers & Annelies Boonen. (2014) A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis. PharmacoEconomics 33:3, pages 205-224.
Crossref
F. J. B. Lötters, I. Lenoir-Wijnkoop, P. Fardellone, R. Rizzoli, E. Rocher & M. J. Poley. (2012) Dairy foods and osteoporosis: an example of assessing the health-economic impact of food products. Osteoporosis International 24:1, pages 139-150.
Crossref
Huifeng Yun, Jeffrey R Curtis, Kenneth Saag, Meredith Kilgore, Paul Muntner, Wilson Smith, Robert Matthews, Nicole Wright, Michael A. Morrisey & Elizabeth Delzell. (2013) Generic alendronate use among medicare beneficiaries: are part d data complete?. Pharmacoepidemiology and Drug Safety 22:1, pages 55-63.
Crossref
Kurt Lippuner, Richard F. Pollock, Jayne Smith-Palmer, Thomas Meury & William J. Valentine. (2011) A Review of the Cost Effectiveness of Bisphosphonates in the Treatment of Post-Menopausal Osteoporosis in Switzerland. Applied Health Economics and Health Policy 9:6, pages 403-417.
Crossref
Dirk Mueller & Afschin Gandjour. (2011) Cost Effectiveness of Secondary vs Tertiary Prevention for Post-Menopausal Osteoporosis. Applied Health Economics and Health Policy 9:4, pages 259-273.
Crossref
Hilal Maradit Kremers, Sherine E. Gabriel & Michael F. Drummond. 2011. Rheumatology. Rheumatology 23 28.e5 .
. (2013) Alendronic acid/colecalciferol more than breaks even. PharmacoEconomics & Outcomes News 548:1, pages 5-5.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.